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ABSTRACT
Introduction The aim of breast reconstruction (BR) is to 
improve patients’ health- related quality of life (HRQOL). 
Therefore, measuring patient- reported outcomes (PROs) would 
clarify the value and impact of BR on a patient’s life and thus 
would provide evidence- based information to help decision- 
making. The Satisfaction and Quality of Life After Immediate 
Breast Reconstruction study aimed to investigate satisfaction 
and HRQOL in Japanese patients with breast cancer who 
undergo immediate breast reconstruction (IBR).
Methods and analysis This ongoing prospective, 
observational multicentre study will assess 406 patients who 
had unilateral breast cancer and underwent mastectomy 
and IBR, and were recruited from April 2018 to July 2019. All 
participants were recruited from seven hospitals: Okayama 
University Hospital, Iwate Medical University Hospital, The 
Cancer Institute Hospital of Japanese Foundation for Cancer 
Research, Showa University Hospital, University of Tsukuba 
Hospital, Osaka University Hospital and Yokohama City 
University Medical Center. The patients will be followed up 
for 36 months postoperatively. The primary endpoint of this 
study will be the time- dependent changes in BREAST- Q 
satisfaction with breast subscale scores for 12 months 
after reconstructive surgery, which will be collected via an 
electronic PRO system.
Ethics and dissemination This study will be performed 
in accordance with the Ethical Guidelines for Medical and 
Health Research Involving Human Subjects published by 
Japan’s Ministry of Education, Science and Technology and 
the Ministry of Health, Labour and Welfare, the modified Act on 
the Protection of Personal Information and the Declaration of 
Helsinki. This study protocol was approved by the institutional 
ethics committee at the Okayama University Graduate School 
of Medicine, Dentistry, on 2 February 2018 (1801-039) and 
all other participating sites. The findings of this trial will be 
submitted to an international peer- reviewed journal.
Trial registration number UMIN000032177.
INTRODUCTION
Background and rationale
Breast cancer is the most common type of 
cancer in Japanese women. One in 11 Japa-
nese women will develop breast cancer over 
the course of her lifetime.1 The number of 
newly diagnosed cases was over 76 000 in 
2014,1 and the incidence rate is increasing. In 
terms of age, the incidence begins to increase 
from the age of 30 years and peaks in the 
40s to the 60s.1 As the survival rate of breast 
cancer increases,2 the health- related quality 
of life (HRQOL) of survivors has become 
more important in deciding the course of 
treatment.
Breast reconstruction (BR) after mastec-
tomy is a surgical option to restore the breast 
shape. It has been recognised as a part of 
comprehensive breast cancer surgery to 
Strengths and limitations of this study
 ► The Satisfaction and Quality of Life After Immediate 
Breast Reconstruction will be the first prospective, 
multicentre study in Japan to investigate satisfac-
tion and health- related quality of life (HRQOL) after 
immediate breast reconstruction (IBR).
 ► Time- dependent changes in BREAST- Q scores after 
reconstructive surgery will be informative and will 
aid patients in decision- making.
 ► The Decision Regret Scale has been added to better 
understand the impact of breast implant recall.
 ► The results of this study may represent the satisfac-
tion and HRQOL of patients in relatively good condi-
tion after IBR.
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improve patients’ HRQOL and satisfaction.3–9 In Japan, 
autologous BR has been covered by the National Health-
care Insurance (NHI) since 2006, while implant- based 
reconstruction has been covered since 2013. The number 
of immediate Breast reconstruction (IBR) cases has 
rapidly increased since that time and reached 4700 in 
2018, with 70% being implant- based procedures.10–12
Despite this, some problems remain for patients making 
BR decisions. BR has potential risks and additional burdens 
compared with mastectomy without BR. Insertion of a sili-
cone breast implant involves risks of infection, rupture 
and deformation caused by capsule contracture,13–15 and 
autologous reconstruction involves the sacrifice of donor 
sites and the risk of flap necrosis.16–18 Evidence- based 
information about the available reconstruction options 
is needed, including the possible complications, HRQOL 
prognosis and patients’ perception of cosmetic results to 
help patients know what to expect after BR.19–21
In the past decade, patient- reported outcomes (PROs) 
have been used to understand how BR impacts a patient’s 
life and to measure the value of BR.7 22–26 Among these 
PROs, the BREAST- Q,24 the first BR- specific instrument, 
has been most commonly used worldwide because of 
its high validity. It enables evaluation of the outcome 
of BR in terms of various aspects, such as aesthetic satis-
faction, physical well- being, psychosocial well- being and 
satisfaction with care. Research conducted using the 
BREAST- Q has provided much of the important infor-
mation about BR.7–9 A recent large prospective cohort 
study in North America, the Mastectomy Reconstruction 
Outcome Consortium, enrolled over 4400 women and 
demonstrated that HRQOL and satisfaction after autol-
ogous reconstruction were higher than after implant- 
based reconstruction, and that postmastectomy radiation 
therapy was better tolerated.9 27 They also investigated the 
recovery phase and reported that many participants may 
not be fully recovered at 3 months postoperatively, regard-
less of the reconstruction procedure, and that patients 
who underwent abdominal- based autologous reconstruc-
tion had lesser chest and upper extremity morbidities.21
Evidence regarding BR is being developed in Western 
countries, although there is very little evidence from 
Japan. Since there are physical, psychological and 
cultural differences between Western and Japanese 
women, investigations in Japanese cohorts are essential 
to improve medical care.4 28 29 The healthcare environ-
ment also differs between countries, and there are some 
limitations in terms of BR performed under medical 
insurance in Japan. The acellular dermal matrix that 
supports the lower pole of the breast in implant- based 
reconstruction,30 which is more commonly used in other 
high- income countries, is not available in Japan; there-
fore, most implant cases require a staged procedure. Risk- 
reducing mastectomy (RRM) for hereditary breast and 
ovarian cancer has been covered by the NHI since April 
2020 and is limited to women who have already devel-
oped breast or ovarian cancer; therefore, currently, fewer 
women in Japan undergo RRM and bilateral BR.31 Types 
of implants covered under the NHI have been limited to 
Allergan products; therefore, Allergan’s July 2019 recall 
of Biocell textured breast implants due to the risk of 
breast implant- associated anaplastic large cell lymphoma 
(BIA- ALCL)32–35 had a significant impact on women who 
had undergone implant- based reconstruction in Japan, as 
well as those who were undergoing the reconstruction.
Objective
The aim of this study, the Satisfaction and Quality of Life 
After Immediate Breast Reconstruction (SAQLA) study, 
was to investigate the satisfaction and HRQOL in Japa-
nese patients with breast cancer following mastectomy 
and IBR to further understand their experience. We will 
focus on differences due to the reconstructive procedure 
so as to provide useful information for decision- making 
in BR. This will be the first prospective, multicentre study 
in Japan to investigate the time- dependent change in 
BREAST- Q scores, which will contribute fundamental data 
for future clinical research leading to new hypotheses and 
evidence for Japanese patients with breast cancer.
In addition, since Allergan’s recall occurred during the 
study period, just before recruitment was closed, we will 
also explore how it affected our participants by watching 
for trends in participants opting out of reconstruction 
surgery or changing their chosen reconstruction proce-
dure, and evaluating their regrets about their decision.
METHODS AND ANALYSIS
Design and setting
This study was designed as a multicentre, longitudinal, 
observational study. All participants were recruited from 
seven major BR hospitals: Okayama University Hospital, 
Iwate Medical University Hospital, The Cancer Institute 
Hospital of Japanese Foundation for Cancer Research, 
Showa University Hospital, University of Tsukuba Hospital, 
Osaka University Hospital, and Yokohama City University 
Medical Center. The study is currently ongoing. Recruit-
ment began in April 2018 and closed in July 2019. A total 
of 406 patients are enrolled in the study and they will be 
followed up for 36 months postoperatively.
Patients and recruitment
The eligible subjects are those diagnosed with initial 
unilateral breast cancer and are scheduled for mastectomy 
and IBR. All participants undergo regular treatment at 
their participating sites. The breast reconstructive proce-
dures include implant- based reconstruction, latissimus 
dorsi flap and abdominal flaps, including deep inferior 
epigastric artery perforator flap, transverse rectus abdom-
inus myocutaneous flap and superficial inferior epigastric 
artery perforator flap, all of which are commonly prac-
tised in Japan. Potential participants were recruited at 
each site before surgery if they fulfilled all the inclusion 
criteria and did not meet any of the exclusion criteria 
(box 1). The time between the diagnosis of breast cancer 
and recruitment into the study was not set. Consenting 
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participants were then registered on the electronic data 
capture (EDC) system and study IDs were given.
Loss to follow-up
Observation will be discontinued if a participant meets any 
of the following conditions: (1) cancellation of BR due to 
patient’s intention or treatment plan, (2) reconstruction 
failure, (3) recurrence or metastasis of breast cancer, (4) 
contralateral breast cancer, (5) malignant diseases other 
than breast cancer, (6) death of participant, (7) with-
drawal of consent and (8) researchers’ judgement that it 
is inappropriate to continue observation.
In this study, reconstructive failure is defined as a condi-
tion in which the reconstructed breast is removed, that is, 
flap loss and implant removal. Patients with reconstruc-
tive failure are rather devastated; we therefore regard the 
administration of a questionnaire about aesthetic satisfac-
tion to be highly inappropriate in these patients. However, 
patients with other complications, such as haematomas, 
capsular contractures or fat necrosis, which may lead to 
impaired aesthetic results, will be followed up.
Outcomes
Primary and secondary outcomes
The primary endpoints of this study are the time- dependent 
changes in BREAST- Q satisfaction with breasts scores over 
12 months after surgery. BREAST- Q evaluations will be 
performed at baseline and at 1, 3, 6 and 12 months post-
operatively, and the scores will be analysed according to 
the BR procedure performed. The secondary endpoints 
include (1) the time- dependent changes in BREAST- Q 
subscale scores, including psychosocial well- being, 
physical well- being and sexual well- being for 12 months 
after surgery; (2) the time- dependent changes in Eight- 
Item Short- Form Health Survey (SF-8) summary score 
and physical and mental component summary score for 
12 months after surgery36; (3) long- term patient satisfac-
tion and HRQOL after IBR evaluated by BREAST- Q and 
SF-8 for up to 36 months; (4) the burden of IBR; (5) the 
complication rate; and (6) bilateral symmetry measured 
by the 4- point Harris Scale37 and Mamma Balance.38
Patient-reported outcomes
We set the questionnaire items for satisfaction and 
HRQOL based on a core outcome set proposed by Potter 
et al.39 BREAST- Q will be used for the measurement of 
satisfaction and HRQOL related to BR. The satisfaction 
with general health, which cannot be evaluated with 
BREAST- Q, will be measured using SF-8.36 Ad hoc ques-
tionnaires to investigate the patient burden associated 
with IBR and motivation for further reconstructive proce-
dures such as revision surgery or nipple reconstruction 
will also be used. Since depression and anxiety of preop-
erative patients may affect the level of postoperative 
satisfaction,40 screening for depression/anxiety will be 
performed with Hospital Anxiety and Depression Scale 
(HADS)41 42 at baseline. The baseline questionnaire also 
includes data on the participants’ social background, 
such as education level, employment, income and marital 
status.
Following the Allergan implant recall, the distress with 
regard to the decision of BR will be assessed using the 
Decision Regret Scale (DRS)43 44 1 year after completing 
BR.
BREAST-Q
BREAST- Q is a self- administrated rating scale consisting 
of 15 subscales and 121 items that measure the effect of 
breast surgery on patient satisfaction and HRQOL. The 
recall period is the past week. There is a score for each 
subscale, and a higher score indicates a higher satisfaction 
level and QOL. The following subscales are used in this 
study: satisfaction with breasts, satisfaction with implant, 
psychosocial well- being, sexual well- being, adverse effects 
of radiation, physical well- being of chest and upper 
extremity, satisfaction with abdomen, physical well- being 
of abdomen, satisfaction with back appearance, and phys-
ical well- being of shoulder and back. A formal Japanese 
version was developed,45 and the validation of the recon-
struction module has been completed (Cronbach α>0.7, 
inter- rater reliability (intraclass correlation coefficient 
(ICC)>0.8).
Eight-Item Short-Form Health Survey
This tool is a self- administered questionnaire consisting 
of eight items to evaluate HRQOL: physical functioning, 
physical role, bodily pain, general health, vitality, social 
functioning, emotional role and mental health. Based 
on the eight subscales, SF-8 can calculate two summary 
scores: a physical and a mental component summary.36
Box 1 Eligibility criteria
Inclusion criteria
1. Pathological diagnosis of breast cancer.
2. Planned total mastectomy (including Bt, SSM and NSM).
3. Breast surgeon determined an indication for BR and IBR is scheduled.
4. Aged between 20 and 75 years.
5. ECOG PS of 0 or 1.
6. Written informed consent provided.
Exclusion criteria
1. Reconstruction for breast conserving surgery.
2. History of breast- conserving surgery.
3. History of ipsilateral BR (re- reconstruction).
4. Heterochronic and simultaneous bilateral breast cancer.
5. Breast shape has been remarkably changed by previous surgery, 
such as augmentation.
6. Difficulty participating in the study due to a mental condition.
7. Doctor indicates unsuitability for the study.
8. No possession of a device such as a smartphone, tablet or PC, and 
inability to respond to the ePRO at home.
BR, breast reconstruction; Bt, mastectomy; ECOG PS, Eastern Cooperative 
Oncology Group Performance Status; ePRO, electronic version of the Patient- 
Reported Outcomes Questionnaire; IBR, immediate breast reconstruction; 
NSM, nipple- sparing mastectomy; PC, personal computer; SSM; skin- sparing 
mastectomy.
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Hospital Anxiety and Depression Scale
HADS is a 14- item questionnaire that evaluates depres-
sion and anxiety. There are seven depression items and 
seven anxiety items which are scored separately. Each 
item is scored from 0 to 3 points, with a maximum 
subscale score of 21. A subscale score of more than 8 
indicates anxiety or depression.42
Decision Regret Scale
DRS is a self- administered questionnaire consisting of 
five items that measures the distress or remorse after 
healthcare decisions. Possible score is 0–100, where 
higher scores indicate stronger regret. A formal Japa-
nese version has been developed.44 In this study, an 
item will be added to determine whether the implant 
recall affected the response to DRS.
Medical history and physical examination
The following medical history and physical examina-
tion data will be collected by researchers from medical 
records: age, breast cancer clinical stage, adjuvant 
therapy, body mass index (BMI), smoking habits, 
glycated haemoglobin, American Society of Anesthesi-
ologists classification, regular administration of steroids 
and breast ptosis. Surgery- related factors to be collected 
on the day of surgery include reconstruction procedure, 
mastectomy procedure (nipple- sparing or skin- sparing 
mastectomy), axillary dissection or sentinel node 
biopsy, and weight of resected specimen. The factors 
that influence whether participants undergo additional 
reconstructive procedures such as nipple reconstruc-
tion, fat injection, revision of reconstructed breast or 
mastopexy of the contralateral breast will be collected 
at 12 and 36 months after reconstruction.
Complications of surgery
Complications related to BR procedures will be divided 
into four categories as follows: (1) complications of the 
breast area common to all procedures: postoperative 
haemorrhage, haematoma, seroma, wound dehiscence, 
wound infection, and skin and nipple–areola necrosis; 
(2) systemic complications common to all procedures; 
(3) complications related to tissue expansion (TE)/
implant, infection or implant explantation; (4) autol-
ogous reconstruction- related complications: emer-
gent additional surgery for blood flow insufficiency, 
flap necrosis, or donor- site complications. Complica-
tions will be graded according to the Japan Clinical 
Oncology Group postoperative complications criteria 
(Clavien- Dindo classification) V.2.0. Complications will 
be reviewed at 1, 12 and 36 months after surgery.
Cosmetic outcomes
Objective cosmetic outcomes of the breast will be eval-
uated by medical staff using photographs taken at 12 
and 36 months after reconstruction. The following two 
methods will be used for evaluation: (1) Harris scale 
(4- point scale)37: classification of the global cosmetic 
outcomes into four categories (excellent, good, fair 
or poor) and (2) Mamma Balance38 software that digi-
tises the position difference between the left and right 
nipples and objectively evaluates bilateral symmetry. 
The ICC of this method is 0.78.
Sample size determination
The sample size was not calculated based on a statis-
tical perspective. The number of target participants 
was determined as 400 patients based on the annual 
number of IBR cases in the participating seven sites and 
consideration of the eligibility criteria.
Data collection and timelines
This study will collect data using EDC systems, Viedoc 
V.4 and ePRO, ViedocMe (PCG Solutions, Sweden). 
Data entry into the electronic case report forms will 
be performed by researchers using the EDC at each 
hospital. The PRO questionnaire will be administered 
to patients using ePRO at nine study time points: at 
baseline and at 1, 3, 6, 12, 18, 24, 30 and 36 postoper-
ative months through the patient’s own device. Partic-
ipants will be given the timeline of the survey and will 
complete the questionnaire in the scheduled survey 
Table 1 Study timeline: patient- reported outcomes
Baseline
Time after breast cancer surgery
1 month 3 months 6 months 12 months 18 months 24 months 30 months 36 months
HADS ●                 
BREAST- Q ● ● ● ● ● ● ● ● ●
SF-8 ● ● ● ● ● ● ● ● ●
Burden of BR   ● ● ● ● ● ● ● ●
Motivation for further 
revision
                ●
DRS         ●*         
*12 months after the second operation for patients who had staged reconstruction.
BR, breast reconstruction; DRS, Decision Regret Scale; HADS, Hospital Anxiety and Depression Scale; SF-8, 8- Item Short- Form Health 
Survey.
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period by accessing the ViedocMe website from a 
browser of their own smartphone. If the patient desires, 
she can register her email address or phone number in 
the Viedoc system and receive notifications to remind 
her of the survey. The central data manager will monitor 
the completion status of the questionnaire and notify 
the researchers at the respective sites of incomplete 
assessments. Thereafter, the researcher will contact the 
participant to request they complete the questionnaire 
within the survey period. Data regarding participants’ 
medical history, physical examination, complications 
of surgery and cosmetic outcomes will be gathered by 
medical staff and entered into the EDC system on the 
web at each site and linked to the PRO data. The study 
timeline is shown in tables 1 and 2.
Data management, data monitoring and auditing
The data centre is located in the Department of Clin-
ical Trial Data Management, Tokyo University Grad-
uate School of Medicine, Tokyo, Japan. No personally 
identifiable information will be entered into the EDC 
to protect participants’ privacy. Data management and 
central data monitoring will be performed using the 
EDC. There will be no data monitoring committee. 
Similarly, auditing is also not planned for this study. 
Following completion of the study, the fixed data will 
be exported and then deleted from the EDC. The data 
will be stored in a public data repository.
Harms
No serious harm is expected in this observational study. 
Some patients might feel psychological distress when 
asked about their sexual well- being.45 The estimated 
time to complete a survey is about 10 min, and this may 
be a burden.
Statistical analysis
The primary analysis of this study will describe the time- 
dependent changes in satisfaction with breasts score 
of the BREAST- Q during the 12- month postoperative 
period. BREAST- Q evaluation will be performed at 
baseline and at 1, 3, 6 and 12 months after surgery, and 
summary statistics at each time point will be calculated 
for each surgical procedure. General linear models, 
which include the reconstruction procedure, time 
point, and time- by- procedure interaction as explanatory 
variables, will be used to summarise the longitudinal 
change of the endpoints. Likelihood- based methods 
will be applied to analyse incomplete data. An unstruc-
tured covariance matrix will be assumed, and robust SE 
will be calculated for estimated parameters. BREAST- Q 
and SF-8 scores will be adjusted for age, BMI, breast 




All investigators involved in the current research will 
conduct this study in accordance with the Declaration 
of Helsinki and Ethical Guidelines for Medical and 
Health Research involving Human Subjects (Public 
Notice of the Ministry of Education, Culture, Sports, 
Science and Technology, and Ministry of Health, Labor 
and Welfare, 2015).
Consent
Before enrolling patients into this study, the researchers 
gave the patients an informed consent form, and the 
details about this study were explained according to the 
Ethical Guidelines for Medical and Health Research 
Involving Human Subjects. All the participants were 
informed that they had the right to withdraw consent 
without any disadvantages.
Trial registration
This study protocol and the informed consent form 
have been approved by the institutional review boards 
at all the participating sites. The study was registered 
with the UMIN Clinical Trial Registry. The protocol 
version is 1.2, 1 January 2020.
Table 2 Study timeline: clinician- reported outcomes
Before breast 
cancer surgery Day of 
surgery
After breast cancer 
surgery After breast reconstruction*
On enrolment 1 month 12 months 1 month 12 months 36 months
Medical history and physical 
examination
●
Surgery- related factors   ●
Review of complications   ● ● ● ●
Review of adjuvant therapy   ●
Review of additional 
reconstructive procedure
  ● ●
Cosmetic outcome
(photograph)
  ● ●
*Second operation for staged reconstruction.
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Access to data
Only clinical data managers at the central data centre 
will have access to the reported case data through the 
EDC system during the study. Site investigators will 
have access to case data within all their sites. The data 
manager will transfer the final dataset to the principal 
investigator and the data will be stored in electronic 
format.
Dissemination policy
The results will be analysed and reported in a form 
in which individuals cannot be identified. The find-
ings of the study will be presented at conferences and 
published in peer- reviewed medical journals domesti-
cally and internationally.
DISCUSSION
Although the number of cases of BR is increasing in 
Japan, the outcomes of BR have not been adequately 
evaluated due to the lack of established outcome 
measures. Considering that the purpose of BR is to 
improve patients’ satisfaction and HRQOL, PROs are 
very useful and essential. SAQLA is the first multicentre 
study in Japan to evaluate BR from this perspective. Our 
data will provide time- dependent changes in BREAST- Q 
and SF-8 scores following mastectomy and IBR. Infor-
mation on the recovery process is helpful for patients 
who are to make BR decisions and can facilitate patient 
engagement in decision- making. It can also serve as 
fundamental data for future clinical research and 
contribute to improving healthcare surrounding BR.
Our patients were mainly recruited from university 
hospitals, although we included patients undergoing 
IBR with implant- based reconstruction, latissimus dorsi 
flap and abdominal flaps, which are commonly used 
techniques in hospitals other than university hospitals. 
Thus, we believe that this study sample will represent 
Japanese women undergoing IBR adequately. BR proce-
dures that are performed only in a limited number of 
facilities, such as gluteal artery perforator flaps, total 
BR with fat graft and BR for breast conserving surgery, 
were not included. Since the trend of the surgical proce-
dure for BR will change with the times, further research 
plans are expected for cases that are not included in 
this study but are expected to increase, such as bilateral 
RRM and BR.
Implant recall has had a significant impact on the 
field of BR in Japan. We cannot rule out the possibility 
that the fear of developing BIA- ALCL might decrease 
satisfaction and HRQOL of our participants, and there-
fore, the study results will be skewed. To account for 
that, DRS has been added to help us understand the 
psychological impact of implant recall while also paying 
attention to the discontinuation of reconstruction 
cases caused by the recall. We also considered making a 
comparison between outcomes of patients with recalled 
implants and those with other types of implants.
There are a few limitations to this study protocol. 
First, this is a hypothesis- generating observational 
study. The number of target participants has not been 
set statistically but is based on the actual number of 
cases in the participating seven sites instead. There-
fore, although we will describe the time- dependent 
changes in PROs following reconstruction procedures, 
this study will not determine the difference between the 
procedures. Second, it was discussed whether the time- 
dependent changes in staged reconstruction should 
start from the primary operation (TE insertion) or 
the second operation (change to permanent implant 
or autologous tissue). The latter can be better at eval-
uating the recovery period of the second operation. 
However, we believe that it would be more beneficial 
to evaluate the physical and psychological well- being 
of patients from the primary operation itself since the 
extent of distress during TE insertion is one of the main 
concerns of patients who need to select an IBR proce-
dure or prepare for surgery. Focusing on 12 months, we 
assume that cases with staged reconstruction would have 
a lower level of satisfaction since the downtime occu-
pies a longer period. We would like to investigate any 
differences in the final aesthetic satisfaction between 
one- stage and staged reconstruction procedures over a 
3- year follow- up period. Third, we cannot obtain results 
of all participants. Patients lost to follow- up may have 
low satisfaction and HRQOL, which can lead to bias; 
that is, the results of this study may represent the satis-
faction and HRQOL of patients in relatively good condi-
tion, rather than represent all cases of IBR. Presumably, 
another research plan will be needed to understand 
how such ‘lost- to- follow- up’ patients cope with the situa-
tion, in order to have a wholistic picture of IBR. Finally, 
our participant group includes only women who choose 
BR. It would be more informative to include women 
who undergo other breast cancer surgeries, such as 
mastectomy without BR and breast conserving surgery. 
This will be investigated in a future study.
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